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The objective of this study was to gain a quantitative understanding of the link between physicochemical
properties and long-term and time-censored amorphous stability of poorly water-soluble drugs using
parametric time-to-event modeling. Previously published data on amorphous stability and physico-
chemical properties of 25 structurally diverse neutral, poorly soluble compounds were used. To describe
the general shape of the survival curve (probability of event at time > t), Constant, Gompertz, and
Weibull hazard functions and their linear combinations were tested. For a selected Weibull hazard base
model, the effect of each physicochemical covariate was investigated, with combined inﬂuence of
enthalpy of fusion (Hf) and molecular weight (Mr) showing the highest statistical signiﬁcance. The
covariate model was used to simulate survival curves and calculate the median survival time for different
values of Hf and Mr. It was found that a decrease in Hf or an increase in Mr contribute to longer survival
times. The derived model equation was validated against external data sets consisting of 11 compounds.
It showed better predictive ability than a previously published multiple linear regression model incor-
porating Hf and Mr. The proposed Weibull covariate model may assist in faster and more cost-effective
decision making in the pre-formulation phase of drug development, where compound properties and
appropriate drug formulation strategies are investigated.
© 2016 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association®. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Small-molecule drug candidates with good pharmacological
properties frequently suffer from low aqueous solubility. For oral
drug products, this can lead to insufﬁcient and erratic bioavail-
ability of the active pharmaceutical ingredient (API), and for that
reason, lipophilic APIs with limiting aqueous solubility are often
formulated in the amorphous state, typically as solid dispersions in
polymer matrices.1 This approach is favorable because the amor-
phous solid state of a molecule is at a higher energy level compared
with its crystalline state, giving rise to higher dissolution rates and
solution concentrations of poorly soluble APIs from amorphousg ﬁnancial interest.
from the authors by request
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ska).
r Inc. on behalf of American Pharmversus crystalline formulations.2 However, on account of the
comparatively disordered and mobile nature of amorphous solids,
APIs can crystallize from amorphous formulations on storage or on
contact with gastrointestinal ﬂuids after administration. Such
instability is a signiﬁcant hurdle in the development of new med-
icines, and it would be highly desirable to be able to predict the
inherent amorphous stability of poorly soluble APIs and the
stability of such molecules in amorphous solid dispersions.
One physical stability classiﬁcation methodology assesses the
glass-forming ability of APIs after rapid solvent evaporation from a
solution or cooling from a melt,3,4 whereas in a different method
the phase transition from the amorphous to a crystalline state is
observed directly as a function of time.5,6 In the former method, the
assumption is that some compounds have an inherent ability to
form amorphous solids from liquids, whereas others more readily
assume a crystalline state on transition from the liquid to the solid
state. It has been observed that the crystallization classiﬁcation of
model APIs is similar, independent, however, of methodology. From
the limited data published to date, it would appear that theacists Association®. This is an open access article under the CC BY license (http://
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properties of the API and other formulation components, rather
than the amorphization methodology itself.4,7 However, environ-
mental conditions, for example, humidity and temperature, can
also affect amorphous drug stability8 and can, therefore, lead to
different results reported by different laboratories. Although the
intrinsic factors affecting ease of compound crystallization from the
amorphous state, such as molecular mobility and thermodynamic
properties of the amorphous state,9 remain poorly understood,
efforts have been underway to correlate observed glass-forming
ability or physical stability of amorphous APIs with physicochem-
ical and other properties of the APIs. Some progress has been made
in the prediction of the physical stability of amorphous APIs.6,10-13
The framework developed on pure APIs in this work can be used
as a preliminary risk assessment for the development of their solid
dispersion formulations. It is expected that the amorphous stability
of solid dispersions will be improved in comparison with pure
drugs due to the dilution effect and the presence of speciﬁc
interactions between a drug and a polymer. Amorphous com-
pounds that are shown to have good amorphous stability should
also be stable in their solid dispersions. Conversely, compounds
that have poor stability may still be formulated as viable solid
dispersions, but the products are likely to have higher risk of
crystallization.
In a previous study,6 the amorphous stability of 25 diverse
neutral poorly soluble drug compounds were investigated. Prin-
cipal component analysis and clustering methods were used to
select 25 compounds with diverse physicochemical properties and
chemical structures from the database of 533 marketed poorly
soluble drugs. The selected sample set was shown to be represen-
tative for the calculated and predicted variables as side-by-side
histograms for both distributions showed the same mean location
and variance.6 Several multiple linear regression (MLR) models
were proposed to predict long-term amorphous drug stability
using only easily accessible physicochemical drug properties as
covariates. Due to practical limitations, continuous crystallization
records during the approximately 6-month period of the experi-
ment were not obtained. Instead, amorphous drug stability was
measured at deﬁned time points, with some compounds remaining
stable at the end of the experiment. Time-to-event (TTE) modeling,
also known as survival analysis,14,15 is particularly suited to this
type of data and was applied in the present study to the previously
published data on 25 diverse compounds. Herewe present the new
application of TTE modeling to more accurately determine the
inﬂuence of physicochemical parameters on the long-term amor-
phous stability of poorly soluble compounds.
A central concept in TTE modeling is the survival function S(t),
which describes the probability that an event will occur at a time
greater than t. The survival function is related to the hazard func-
tion h(t), which can be understood as the instantaneous failure rate
(onset of amorphous to crystalline transition in this study) given
that the compound has survived to that point in time. The survival
and hazard functions are related through Equation 1.
SðtÞ ¼ exp
0
@ Z
t
0
hðtÞ dt
1
A (1)
In parametric TTE modeling, a base model is ﬁrst derived using
a process in which various hazard functions h(t) are proposed, and
estimates of the parameters of the hazard functions are deter-
mined using maximum likelihood estimation. This involves inte-
gration of the hazard function from zero to the time of each
crystallization event, giving the contribution of each event to the
total likelihood, where the parameter estimates are derived bymaximizing the sum of all likelihood contributions with respect to
the parameter values. This estimation process is applied to each of
the candidate hazard functions, and the best function is selected
based on model selection criteria and graphical comparison of
observed and predicted data. Once a hazard function has been
selected, a covariate analysis is performed where the physico-
chemical properties of the compounds are allowed to inﬂuence
the parameters within the hazard function. Model selection
criteria are then used to select a ﬁnal covariate model where the
included covariates produce a statistically signiﬁcant improve-
ment compared with the base model. The model can then be used
to simulate the expected behavior of new compounds with
different values of the included covariates.
Methods
Software
The TTE models were developed using NONMEM software,16
version 7.3 (Icon Development Solutions, Ellicott City, MD). All
other analyses and visualization of data were implemented using R
software17 and use of the “survival” library, version 2.38,18 and the
“deSolve” library, version 1.11.19
Database Preparation
Previously published data of physicochemical properties and
amorphous stability of 25 compounds6 were used to derive a TTE
model. For 17 of the compounds, the precise time of detectable
transition from amorphous to crystalline structure is unknown. It
was only recorded that the transition took place between 2
observation times. Such data are called interval-censored and
were ﬂagged on both sides of the interval within the database
used for modeling (Supplementary Material A). For the remaining
8 compounds, observations were ﬂagged as right-censored
because crystallization was not observed during the 168 days of
experiment. This vector of ﬂag values was used as a dependent
variable. The elapsed time of the interval and right-censored ob-
servations were included as main independent variable. The
following measured, calculated, and predicted physicochemical
properties of the 25 compounds6 were also tested during devel-
opment of the covariate model: enthalpy of fusion (Hf), glass
transition temperature (Tg), melting temperature (Tm), conﬁgura-
tional entropy (Sc), enthalpy (Hc) and free energy (Gc), relaxation
time (t), molecular weight (Mr), hydrogen bond donors and ac-
ceptors, rotatable bonds (rotB), number of rings, aromatic rings,
aliphatic rings, heavy atom count, ratio of carbon to heteroatoms,
polar surface area, lipophilicity (clogP), and water solubility
(logSw) predicted both with CLab6,20 and ALOGPS21 (www.vcclab.
org). These descriptors have been shown in the literature to
have an impact on the glass-forming ability and amorphous sta-
bility,3,11 drug bioavailability,22 and the stability of compounds
formulated as solid dispersions.23
Model Building and Selection Criteria
For selection of an appropriate base model, 8 different hazard
functions were evaluated (Table 1).24 The hazard functions are
deﬁned with parameters l and b which determine the shape of the
hazard function (Supplementary Material B). Because hazard func-
tions must always be positive, the lambda parameters (lc, l1, and l2)
were constrained to positive values during parameter estimation,
whereaspositiveornegativeestimatesof thebetaparameters (bc and
b1) were permitted. The parameter values in the TTE models were
estimated using the ﬁrst-order conditional estimation method,
Table 1
Hazard Functions Tested During Selection of the Base Model
Hazard Function Deﬁnition
Constant hðtÞ ¼ lc
Gompertz hðtÞ ¼ l1$expðb1$tÞ
Weibull hðtÞ ¼ l1$expðb1$lnðtÞÞ
Constant þ Gompertz hðtÞ ¼ lc þ l1$expðb1$tÞ
Constant þWeibull hðtÞ ¼ lc þ l1$expðb1$lnðtÞÞ
Gompertz þ Gompertz hðtÞ ¼ l1$expðb1$tÞ þ l2$expðb2$tÞ
Weibull þWeibull hðtÞ ¼ l1$expðb1$lnðtÞÞ þ l2$expðb2$lnðtÞÞ
Gompertz þWeibull hðtÞ ¼ l1$expðb1$tÞ þ l2$expðb2$lnðtÞÞ
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functionvalue (OFV) and, thus, obtain the bestmodelﬁt to thedata.25
The direction inwhich theOFVdecreases toﬁnd theglobalminimum
was determined in an iterative process using the gradient method.26
To ensure convergence to the global minima, models were run
repetitively, each time starting from different initial parameter esti-
mates. The global minimumwas considered to be reached when all
repetitive runs resulted in the same ﬁnal parameter estimates and
OFVs. Estimates of parameter uncertainty (standard error) were
generated using the NONMEM covariance procedure.16
Models were ﬁrst required to pass the following acceptance
criteria27:
1. At the last iteration, the values of the gradients have to be be-
tween 106 and 10 to indicate that the OFV successfully
converged to its minimum.
2. The covariance step, where uncertainty in parameter estimates
is determined, has to complete successfully.
3. The number of signiﬁcant digits of parameter estimates has to
be 3.
4. The correlation between estimated parameters, cp, has to
be 0.95  cp  0.95. This criterion will reject models that are
overparametrized.
5. The ratio of maximum to minimum eigenvalues of the correla-
tionmatrix of parameter estimates (condition number) has to be
1000. This criterion will reject models that are
overparametrized.
6. The standard error of each parameter estimate is required to be
<50% of the estimated parameter value. This ensures that the 95%
conﬁdence interval for the parameter estimate excludes zero.
For those models that passed the acceptance criteria, the base
model (Table 1) was then selected using Akaike information crite-
rion (AIC). This criterion is used to compare nonnested models,
where ﬁxing one parameter in the ﬁrst model to its null value is not
leading to the second model. According to this criterion (Eq. 2), a
model (A) is statistically superior to a model (B) if AIC <0.
AIC ¼ OFVmodel A  OFVmodel B þ 2ðnmodel A  nmodel BÞ (2)
where n is the number of model parameters.
The inﬂuence of covariates on the parameters of the selected
base model was then tested using the forward inclusion method.
Covariate effects were assessed one by one followed by evaluation
of the combined effect of signiﬁcant covariates. The effect of each
covariate, COV, was modeled relative to the median value of that
covariate, COVmedian, in the sample set28 according to Equation 3.
COVm ¼ COV COVmedian (3)
Covariate models of 2 different types were tested. When testing
the inﬂuence of a covariate on a l parameter, l as given by the
equations in Table 1 was replaced by lcov as deﬁned by Equation 4lcov ¼ l$expðq$COVmÞ (4)
where q is a new parameter, estimated by the modeling software,
which quantitatively describes the inﬂuence of the covariate on the
hazard function. The functional form of Equation 4 enables the
possibility that an increase in the covariate can increase or decrease
themagnitude of the hazard function (positive or negative estimate
of q) while satisfying the constraint that the hazard function should
always be positive. When testing the inﬂuence of a covariate on a b
parameter, a different functional form of the covariate model was
used as deﬁned by Equation 5.
bcov ¼ b$ð1þ q$COVmÞ (5)
This different functional form allows the possibility of changes
in the covariate inﬂuencing themagnitude and sign of the original b
parameter because both positive and negative values of bcov are
permitted (they both lead to a positive hazard function). The forms
of Equations 4 and 5 also ensure that if the covariate parameter q is
zero, then the hazard function reduces to that of the base model.
The signiﬁcance of the covariate models was assessed using the
likelihood ratio test (LRT).14 The covariate was considered to have a
signiﬁcant effect if the decrease in the OFV of the covariate model
from that of the base model was >6.63 (p value < 0.01). This
stringent p value was used due to the inﬂated type I error that
occurs during multiple testing (testing of many possible covariate
relationships). For the ﬁnal covariate model, the estimates of
parameter uncertainty produced by the NONMEM covariance
procedure were supplemented by a more thorough bootstrap
procedure implemented using PsN software.29 This involved taking
the structure of the ﬁnal covariate model and repeatedly ﬁtting it to
1000 data sets, each produced by sampling with replacement from
the original data set of 25 compounds. This provided 1000 esti-
mates of each model parameter. Then 95% nonparametric conﬁ-
dence intervals were generated from the 2.5 and 97.5 percentiles of
the 1000 parameter estimates.Model Qualiﬁcation
The ﬁnal covariate model was qualiﬁed using a visual predictive
check (VPC), which involves assessment of the concordance
between the observed crystallization events and repeated simula-
tions of crystallization events from the selected model.30-32 To
generate the VPC, the selected covariate model was used to simu-
late 1000 sets of event times for the 25 compounds. Then, using the
survival library in R, KaplaneMeier survival curves with 95% con-
ﬁdence intervals were plotted for the observed events and for the
2.5, 50, and 97.5 percentiles. A good model should show extensive
overlap of the conﬁdence intervals derived from the observed and
simulated event data with little evidence of bias. The simulated
event times were generated through numerical integration (using R
library deSolve) of h(t) to give S(t). This was followed by repeated
sampling of random numbers from a uniform distribution in the
interval 0 to 1 (because S(t) is uniformly distributed on the interval
0 to 1)24 and ﬁnding corresponding times at which the survival
function became less than or equal to the sampled random number.
Adjustment of the simulated event times according to the sched-
uled experimental measurement times (1 hour, 3 hours, 1 day,
7 days, 1 month, 2 months, 4 months, and 6 months)6 was neces-
sary to allow correct comparison with the interval-censored nature
of the observed data. For example, if a particular simulated event
time was 4.63 days, it would be adjusted to 7 days because that is
the ﬁrst point in time where the crystallization event could have
been observed according to the experimental schedule.
Figure 1. Visual assessment of candidate base models. KaplaneMeier curve of
observed data is shown as continuous black line with 95% conﬁdence intervals shown
as black dashed lines. KaplaneMeier curves of estimated survival functions derived
from 4 candidate base models are shown as colored lines.
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Selection of the Base Model
The 8 hazard functions tested for selection as base model were
Constant, Gompertz, and Weibull functions and their linear com-
binations (Table 1). Parameter estimates, OFV, and selection criteria
status for the 8 candidate base models are given in Table 2. The last
4 models were immediately rejected due to failure of acceptance
criteria. Failure was either due to an unacceptably wide standard
error in one or more parameter estimates or to unsuccessful
completion of the NONMEM covariance procedure that generates
the standard errors. The latter occurred due to numerical instability
with the Constant þ Weibull model where the parameter lc opti-
mized to a vanishingly small value. Figure 1 shows the 4 models
that passed the acceptance criteria, where the estimated survival
curves derived from the models are shown superimposed on the
KaplaneMeier plot of the observed crystallization events. The
Weibull and Constant þ Gompertz models clearly match the
observed KaplaneMeier curve better than the Constant and Gom-
pertz models. The 2 former models have OFVs that are lower than
the latter 2; therefore, a selection between the Weibull and
Constant þ Gompertz model was the only decision required.
Selection of the base model from the 2 remaining models was
initially performed using a consideration of AIC alone. The
Constantþ Gompertz model has an OFV that is 2.8 units lower than
the Weibull model (Table 2) but has 1 additional parameter
(Table 1). This leads to an AIC of 0.8 in favor of the Constant þ
Gompertz model. It should be noted from Table 2 that the standard
errors of all 3 parameter estimates in the Constant þ Gompertz
model are close to 50% of the parameter estimates, whereas the
precision of parameter estimates in the Weibull model is consid-
erably better. During early attempts to build covariate models using
the initially selected Constant þ Gompertz base model, it was soon
found that the additional complexity arising from incorporation of
covariatemodels caused all parameters to have standard errors that
were >50% of the associated parameter estimate. Due to its addi-
tional complexity, the Constant þ Gompertz model appears to be
less stable than the Weibull model and is likely to be over-
parameterized when covariates are added. Hence, the selection of
the most appropriate base model was reassessed, and the Weibull
model was chosen on the basis that it has an OFV only 2.8 units
higher than the Constant þ Gompertz model. It leads to a similar
visual concordance with the observed KaplaneMeier curve (Fig. 1)
but with the advantage of one fewer parameter and more precise
parameter estimates.
Selection of the Covariate Model
The individual and combined effects of calculated, predicted,
and measured compound properties6 on the parameters l1 andTable 2
Parameter Estimates and OFV From Base Models
Hazard Function OFV 103 lc (d1) 103 l1 (d1) 10
Constant 410142.8 10.5 (2.55)a e e
Gompertz 410107.9 e 72.3 (24.8)a 5
Weibull 410096.5 e 78.2 (19.4)a 6
Constant þ Gompertz 410093.7 3.91 (1.60)a 475 (227)a 8
Constant þWeibullb 410096.5 <5106 78.2 6
Gompertz þ Gompertz 410089.9 e 472 (235)a 9
Weibull þWeibull 410096.5 e 34.8 (3200)a 6
Gompertz þWeibull 410091.4 e 342 (245)a 8
a Standard errors of parameter estimates, derived using NONMEM covariance method
b Covariance procedure did not complete successfully.b1 in the Weibull hazard function were investigated. The LRT was
used to decide if incorporation of a particular covariate led to a
signiﬁcant improvement in the model, with the requirement of a
decrease in the OFV of the covariate model with respect to the base
model of >6.63. Based on this criterion, none of the covariates were
found to have a signiﬁcant effect on b1 and 4 covariates were found
to have a signiﬁcant effect on l1 when tested independently: Hf
(DOFV ¼ 13.46), Mr (DOFV ¼ 10.33), heavy atom count
(DOFV ¼ 9.79), and number of rings (DOFV ¼ 7.84). Further-
more, a model involving the inﬂuence of bothHf andMr on l1 gave a
further signiﬁcant decrease in OFV (DOFV ¼ 23.91). Additional
inclusion of a multiplicative interaction term between Hf andMr to
the latter model did not further improve this model signiﬁcantly
given the use of an additional estimated parameter
(DOFV ¼ 26.14). Attempts to include either heavy atom count or
number of rings as an additional covariate in this model did not
lead to a further signiﬁcant reduction in OFV according to the LRT.
This is likely due to heavy atom count and number of rings being
signiﬁcantly correlated with Mr; hence, they are unable to
contribute signiﬁcantly to further explanation of variability in the
data. The correlationmatrix for all variables used inmodel selection
is shown in Supplementary Material C. The ﬁnal selected covariate3 b1 (d1) 103 l2 (d1) 103 b2 (d1) Acceptance Criteria Met
e e Yes
7.8 (16.5)a e e Yes
92 (68.5)a e e Yes
54 (361)a e e Yes
92 e e No
26 (415)a 13.2 (8.69)a 20.7 (12.3)a No
92 (132)a 43.4 (3200)a 692 (114)a No
47 (457)a 36.3 (25.1)a 578 (180)a No
.
K. Nurzynska et al. / Journal of Pharmaceutical Sciences 105 (2016) 1858e18661862model, therefore, included the inﬂuence of Hf and Mr on l1. The
hazard function for this model is given in Equation 6 (where 72.92
is the median Hf and 406.56 is the median Mr), the parameter es-
timates are given in Table 3, and the NONMEM control ﬁle is shown
in Supplementary Material D.
hðtÞ ¼ l1$expðb1$lnðtÞÞ$exp

q1

Hf  72:92

þ q2ðMr  406:56Þ

(6)
The estimate of parameter q1 is positive which indicates that an
increase in Hf leads to an increase in h(t) and, hence, a decrease in
stability of amorphous compounds. This directional inﬂuence is
entirely consistent with a larger enthalpy of fusion leading to a
greater thermodynamic driving force toward crystallization.
Contrarily, q2 has a negative estimate such that an increase in Mr
leads to an increase in amorphous drug stability. The positive ef-
fects of highMr and lowHf on amorphous stability determined here
are consistent with the earlier MLR analysis of the same data set6
and also with other literature reports.3,9,10 The MLR study found
that both Mr and Hf were individually correlated with amorphous
stability (R ¼ 0.59 and R ¼ 0.73, respectively) and the model
equation involving both covariates is given by Equation 7.
logðStabilityÞ ¼ 0:00309Mr  0:0265Hf þ 1:92: (7)
Itwaspreviously reported thatmoleculeswithhighMroftenhavea
complex structure that impedes orientation in a crystal lattice, which
leads to higher stability in a disordered, amorphous state.3 Molecules
with high Hf require more energy to disrupt the crystalline lattice
during melting. Asmelting precedes the formation of the amorphous
material, the energy supplied during melting increases the internal
energy of the system and, thus, lowers its physical stability.6
The 95% conﬁdence intervals around the parameter estimates in
Table 3 were derived from a nonparametric bootstrap procedure
which involved ﬁtting of the model to 1000 different data sets of 25
compounds, each sampled (with replacement) from the original
data set.29 The distributions of parameter estimates for the 4 model
parameters, derived from the bootstrap procedure, are shown in
Figure 2, and the 95% conﬁdence intervals in Table 3 were derived
from the 2.5 and 97.5 percentiles of each distribution. The 95%
conﬁdence intervals around the estimates of l1, b1, and q1 all
exclude the null value of zero, but the conﬁdence interval around q2
does include zero by a small margin. However, the inclusion of q2 in
the model does satisfy the requirement of the LRT because the OFV
reduces by 10.45 on addition of the inﬂuence of Mr to a simpler
model that only includes the inﬂuence of Hf. It is likely that adding
more compounds to the sample set for a future analysis would lead
to a more precise estimate of q2.
It is important to recognize that the generation of events using a
TTEmodel is a stochastic process and repeated simulations of event
times from themodelwill be different andwill encompass a rangeof
values.24 A suitable method for qualiﬁcation of such a model is the
VPC,which involves repeatedsimulationsof themodel followedbya
visualization (using KaplaneMeier curves) of the observed events
and the range of simulated events.30 This diagnostic plot helps toTable 3
Parameter Estimates of the Selected Weibull Covariate Model
Parameter Estimate 95% Conﬁdence Interval From Bootstrap
l1 (1/d) 0.0630 0.0246: 0.110
b1 (1/d) 0.458 0.574: 0.181
q1 (g/J) 0.0560 0.0381: 0.0999
q2 (mol/g) 0.00771 0.0148: 0.00341ensure that repeated simulations of event times from themodel are
consistent with the observed event times, without evidence of sig-
niﬁcant bias. A VPC of the selected Weibull covariate model was
generatedusing 1000 repeated simulations of event times for the set
of 25 compounds. The results are shown in Figure 3, which indicates
a very good concordance between the KaplaneMeier curve (and
associated 95% conﬁdence interval) of the observed crystallization
events and the median of the 1000 KaplaneMeier curves (and
associated 95% conﬁdence interval) derived from simulated data.
There is substantial overlap between the 2 sets of conﬁdence in-
tervals, and there is no indication of any signiﬁcant bias,which could
beobserved indifferent relative positionsof observedand simulated
KaplaneMeier curves over long periods of time. This conﬁrms that
the selectedWeibull covariatemodel gives a good description of the
experimental data.
Sensitivity Analysis
A sensitivity analysis was performed to investigate and visualize
the effect of the selected covariates on the expected median event
time for crystallization. The Weibull covariate model hazard func-
tion (Eq. 6) was analytically integrated to generate the associated
survival function (Eq. 1).24 The resulting survival function is given
by Equation 8
SðtÞ ¼ exp
 
 K$t
b1þ1
b1 þ 1
!
(8)
where K is given by Equation 9
K ¼ l1$exp

q1

Hf  72:92

þ q2ðMr  406:56Þ

: (9)
The expression for S(t) given by Equation 8 can now be plotted
for different values of Hf and Mr to explore the sensitivity of S(t) to
±20% changes in Hf andMr around values of 100 J/g and 500 g/mol,
respectively. Given that the model contains signiﬁcant uncertainty
in the estimates of the 4 parameters in Equation 6, it was decided
that parameter uncertainty should be incorporated into the sensi-
tivity analysis. Hence, for each ﬁxed pair of Mr and Hf values, S(t)
was calculated 1000 times using the 1000 sets of parameter esti-
mates derived from the bootstrap procedure. At each time point,
the median of the 1000 S(t) values was calculated along with 80%
conﬁdence intervals leading to the plots shown in Figure 4. These
plots indicate that 20% changes in both Hf and Mr lead to highly
signiﬁcant changes in the survival curves for amorphous stability.
The sensitivity to changes in Hf is greater than changes in Mr such
that the example ±20% changes in Hf lead to 7.9-fold changes in
median crystallization time, whereas ±20% changes in Mr lead to
4.1-fold changes in median crystallization time. Note that Figure 4b
contains signiﬁcantly wider conﬁdence bands than Figure 4a, and
this is related to the greater uncertainty in estimation of q2
compared with q1 (Table 3).
If parameter uncertainty is neglected, the sensitivity analysis can
be reduced to a simpler format by taking the expression for S(t) in
Equation 8, setting it equal to 0.5, and then solving the equation for t,
which is equivalent toﬁnding themedian crystallization time rather
than the entire survival curve including parameter uncertainty for a
particular combination of both Hf andMr. This leads to Equation 10
t ¼ exp

1
b1 þ 1

$ln
ðb1 þ 1Þ$lnð0:5Þ
K
 
(10)
The median crystallization time for various combinations of Hf
and Mr was calculated using Equation 10 and is shown in Table 4.
The explored ranges of Hf and Mr led to a 17,000-fold range in
Figure 2. Distributions of parameter estimates derived from bootstrap analysis of Weibull covariate model.
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inﬂuence that Hf and Mr are expected to have on the amorphous
stability of compounds with different properties.
It should be remembered that the generation of predictions
using a TTE model is a stochastic process (even when parameter
estimates are very precise), and once a model has been derived,
the process of predicting event times involves the drawing of
samples from a probability distribution. Hence, the crystalliza-
tion times listed in Table 4 represent the median expected
crystallization times that might be observed for large pop-
ulations of compounds representing each of the combinations of
Hf and Mr. There will be considerable variation in the predicted
crystallization times of particular compounds around each of
the median values. This is consistent with reports in the liter-
ature that compounds with similar physicochemical properties
and chemical structure can demonstrate very different amor-
phous stability.8 This is also true for the data set studied here,
for example, celecoxib (Hf ¼ 72.2 J/g, Mr ¼ 358.8 g/mol, stable
for 6 days) and etoricoxib (Hf ¼ 84.1 J/g, Mr ¼ 381.4 g/mol, stable
for 84 days).Figure 3. VPC of the selected covariate model showing KaplaneMeier curves of observed eve
95% conﬁdence intervals of observed events and the gray shading show the 95% conﬁdencValidation on External Data Sets
A test set of 11 compounds, obtained from the literature3 and
from AstraZeneca,6 was used to validate the derived Weibull co-
variate model. The observed crystallization times of the 11 test set
compounds are given in Table 5. Because only the time of ﬁrst
detection of crystallization was known for these compounds,
without knowledge of the time of the previous observation where
crystallization was not detected, the crystallization times are less
informative than the interval-censored data used for building the
model. TheWeibull covariatemodelwas used to predict 1000 sets of
crystallization times for the 11 compounds, and the observed and
simulated events are displayed in Figure 5 using the same display
format as that used for the VPC in Figure 3. This shows considerable
overlap of the 95% conﬁdence intervals derived from the observed
and predicted data and exhibits a very similar shape of the observed
andmedian predicted KaplaneMeier curves. Therefore, the range of
crystallization event times predictedby theWeibull covariatemodel
are consistent with the observed event times, which indicates that
themodel has the ability to generate useful quantitative predictionsnts (black line) and median of simulated events (red line). The dashed lines indicate the
e interval of the simulated events.
Figure 4. Sensitivity analysis showing differences in survival curves on changes in the model covariates. (a)Mr is constant and Hf changes by ±20%. (b) Hf is constant andMr changes
by ±20%. The colored areas show 80% conﬁdence intervals based on percentiles.
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Further details of the distributions of predicted crystallization event
times are given in Supplementary Material E. We have previously
correlated our experimentally observed amorphous stability values
with those observed elsewhere using a range of different method-
ologies.6 Furthermore, the relative amorphous stability ranges for
the compounds in our validation data set (Table 5) are in line with
the high (indoprofen3,20,26), intermediate (droperidol3,26,33 and
nifedipine3,26,34), and low (clotrimazole3,26,34,35 and felodi-
pine3,26,34) crystallization tendencies reported in the literature.
Although the representation of the model’s predictive power
given in Figure 5 indicates that the overall predictive performance
is about as good as it could be expected, some of the individualTable 4
Median Crystallization Times (days) for Different Combinations of Hf (J/g) and
Mr (g/mol) Calculated Using Equation 10 and Parameter Estimates From Table 3
Mr
Hf
300 350 400 450 500 550
50 63.2 128.8 262.3 534.1 1088 2215
60 22.5 45.8 93.3 190.1 387.1 788.3
70 8.01 16.31 33.21 67.6 137.7 280.5
80 2.85 5.80 11.82 24.07 49.02 99.83
90 1.01 2.07 4.21 8.57 17.4 35.53
100 0.36 0.74 1.50 3.05 6.21 12.64
110 0.13 0.26 0.53 1.09 2.21 4.50
Median crystallization times longer than 168 days are shaded in green (very stable
compounds) and shorter than 1 week are shaded in red (very unstable compounds).predictions in Table 5 have large discrepancies. These discrepancies
may be related to differences in preparation methods and storage
conditions for the test set compounds compared with the com-
pounds used in model building. For instance, felodipine was a
member of the 25 compound training set6 and classiﬁed as an
unstable compound (measured crystallization within 5 days of
storage) and was also a member of the test set where it had been
assessed as a fairly stable compound (crystallization within 84
days).3 It may be possible to further improve the model by
including additional covariates in the future which have not yet
been explored in the present study.
We should note that each of the 11 test set molecules represents
a single sample from a corresponding large population of possible
molecules, with each population having the appropriate pair of Hf
and Mr values. Each of those populations will exhibit a range of
amorphous stability. Furthermore, given the earlier discussion of
the stochastic nature of TTE models, we can understand that the
predicted crystallization times arise from distributions of values.Table 5
Amorphous Stability Data for 11 Compounds Along With Prediction From MLR and
TTE Models. Amorphous Stability Predicted With TTE Is Represented as the Median
of the Simulated Event Times. Event Times Were Generated Up to 168 Days
Compound Stability (d)
Observed Predicted With MLR Predicted With TTE
Indoprofen 0.004 1.63 0.02
Droperidol 1 5.13 0.7
Nifedipine 1 3.87 0.3
Clotrimazole 84 6.25 1
Felodipine 84 12.7 8
1 <14 12 16
2 5-14 8.3 11
3 <1 1 0.3
4 >40 1806.9 168
5 168 11.2 18
6 <1 123.6 168
Figure 5. Assessment of predictive performance of the Weibull covariate model on 11 test set compounds.
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should be viewed as having signiﬁcant variability. The presence of
some test set compounds with large discrepancy between the 2
times is to be expected. The variability in the predictions is toler-
able as the derived model is not intended to replace the need for
empirical drug stability studies and it would not be used in isola-
tion to make critical decisions related to product development. The
model should be rather viewed as a “risk assessment” tool to rank
the relative amorphous stability of compounds, for example, in a
discovery or early development setting, where there is a require-
ment from a biopharmaceutical or solid-state consideration for an
amorphous drug formulation.
To compare the predictive abilities of the TTE model (Eq. 6) and
the published MLR model (Eq. 7), the values of geometric mean-
fold error (GMFE) and bias36 were calculated for both models.
These model predictivity metrics are listed in Table 6. The GMFE of
the MLR model was 33% higher than the GMFE of the Weibull
covariate model, and the bias was lower for the TTE model. This
indicates that the predictive performance of the TTEmodel is better
than the MLR model. This is consistent with the fact that a TTE
analysis is, for several theoretical reasons, better suited to analysis
of event versus time data (particularly given the interval-censored
and right-censored nature of the data) than MLR.Concluding Remarks
In this work, we discussed a novel application of TTE modeling
to better understand the inﬂuence of physicochemical parameters
on measured long-term amorphous stability with censoredTable 6
Metrics Comparing Predictive Performance of TTE and MLR Models When Tested on
11 External Compounds
Model GMFE Bias
MLR 10.10 1.63
TTE 6.73 0.30observations. This study used a previously published set of 25
representative poorly soluble compounds. The best description of
the shape of the survival curve for the measured data was obtained
with a Weibull hazard model consisting of 2 structural parameters,
l1 and b1. After investigating the effect of different physicochemical
properties on l1 and b1, the enthalpy of fusion (Hf) and molecular
weight (Mr) signiﬁcantly improved the model statistics. Using
sensitivity analysis, it was shown that a decrease in Hf and an in-
crease in Mr contribute to longer survival times of amorphous
compounds and that amorphous stability depends more strongly
onHf than onMr. TheWeibull covariatemodel was used to calculate
the median survival times for different values of Hf and Mr. The
resulting survival times can serve as a useful indication of how
amorphous drug stability typically responds to changes in Hf and
Mr but with the realization that signiﬁcant discrepancies are to be
expected. Finally, the Weibull covariate model was tested on an
external data set of 11 compounds and showed superior predictive
power compared with a previously published MLR model, which
also has a dependence on Hf and Mr. Because the 2 used covariates
are readily accessible, through calculation and by means of differ-
ential scanning calorimetry, they may be of interest to the phar-
maceutical industry in time- and cost-effective assessment of
compound stability on storage and development of amorphous
products. However, it will be beneﬁcial to study additional com-
pounds in the future to increase the data set and consequently
reduce the uncertainty in the model parameter estimates.
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